Abstract
Ovarian cancer is an extremely aggressive disease in which the vast majority of patients face a very poor prognosis. Although most patients initially respond to current chemotherapeutic regimens that include a combination of platinum- based therapy (cisplatin/carboplatin) and paclitaxel, the vast majority of them quickly relapse and develop increased resistance to available treatments. Thus, intrinsic and acquired chemotherapy resistance is a major obstacle in the treatment of ovarian cancer patients. Consequently, the priorities for basic and translational ovarian cancer research need to include the identification of novel therapies directed against key molecular targets and signaling pathways in platinum resistant disease. At the same time, we need to develop novel systems for drug delivery aimed at increasing the efficacy and reducing the toxicity of platinum-based treatments. Improving the current responses to platinum chemotherapy is critical not only for achieving a better outcome clinically, including a longer survival, but also for allowing patients to have a better quality of life while in treatment.
Keywords: Combination therapy, CSC pathways, nanotechnology based platforms, oncomap and tumor sequencing, ovarian cancer stem cell markers, platinum resistance.
Current Medicinal Chemistry
Title:Targeting Platinum Resistant Disease in Ovarian Cancer
Volume: 21 Issue: 26
Author(s): S.L. Morgan, J.E. Medina, M.M. Taylor and D.M. Dinulescu
Affiliation:
Keywords: Combination therapy, CSC pathways, nanotechnology based platforms, oncomap and tumor sequencing, ovarian cancer stem cell markers, platinum resistance.
Abstract: Ovarian cancer is an extremely aggressive disease in which the vast majority of patients face a very poor prognosis. Although most patients initially respond to current chemotherapeutic regimens that include a combination of platinum- based therapy (cisplatin/carboplatin) and paclitaxel, the vast majority of them quickly relapse and develop increased resistance to available treatments. Thus, intrinsic and acquired chemotherapy resistance is a major obstacle in the treatment of ovarian cancer patients. Consequently, the priorities for basic and translational ovarian cancer research need to include the identification of novel therapies directed against key molecular targets and signaling pathways in platinum resistant disease. At the same time, we need to develop novel systems for drug delivery aimed at increasing the efficacy and reducing the toxicity of platinum-based treatments. Improving the current responses to platinum chemotherapy is critical not only for achieving a better outcome clinically, including a longer survival, but also for allowing patients to have a better quality of life while in treatment.
Export Options
About this article
Cite this article as:
Morgan S.L., Medina J.E., Taylor M.M. and Dinulescu D.M., Targeting Platinum Resistant Disease in Ovarian Cancer, Current Medicinal Chemistry 2014; 21 (26) . https://dx.doi.org/10.2174/0929867321666140414102701
DOI https://dx.doi.org/10.2174/0929867321666140414102701 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity
Current Pharmaceutical Design The Phosphoinositide Signal Transduction Pathway in the Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Biocatalyzed On Water Synthesis of Chiral Building Blocks for the Preparation of Anti-Cancer Drugs: a GreenerApproach
Current Organic Chemistry Potential Therapeutic Targets for Steroid-Resistant Asthma
Current Drug Targets Virtual Screening of Anti-Cancer Compounds: Application of Monte Carlo Technique
Anti-Cancer Agents in Medicinal Chemistry Lysophospholipid Receptors as Potential Drug Targets in Tissue Transplantation and Autoimmune Diseases
Current Pharmaceutical Design Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cells: Regulation of Expression of Cancer-Related Genes by Estradiol and Tamoxifen
Current Signal Transduction Therapy NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Phosphonic Esters and their Application of Protease Control
Current Pharmaceutical Design Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse
Anti-Cancer Agents in Medicinal Chemistry Subject Index to Volume 10
Current Pharmaceutical Design Transcriptome Analysis of MDA-MB-231 Cells Treated with Fumosorinone Isolated from Insect Pathogenic Fungi
Anti-Cancer Agents in Medicinal Chemistry Recent Patents of Gene Sequences Relative to the Phosphatidylinositol 3-kinase / Akt Pathway and their Relevance to Drug Discovery
Recent Patents on DNA & Gene Sequences Anatomic Site-Related Expression of Cancer-Associated Molecules in Ovarian Carcinoma
Current Cancer Drug Targets MicroRNAs and Pancreatic Cancer: Current Research and Future Outlooks
Current Signal Transduction Therapy Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry Metallodrug Conjugates with Steroids and Selective Estrogen Receptor Modulators (SERM)
Current Medicinal Chemistry Double Strand Break Repair Activities of p53 as Potential Tumor Suppressor Function Counteracting Mammary Tumor Development
Current Women`s Health Reviews